Novartis’ trial of Entresto reveals potential beyond HFrEF treatment
Category: #health  By Pankaj Singh  Date: 2019-11-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Novartis’ trial of Entresto reveals potential beyond HFrEF treatment

Swiss pharma-company Novartis has reportedly revealed subgroup results from its global PARAGON-HF Phase III study. The trial involved a study of patients suffering from HFpEF (heart failure with preserved ejection fraction) or diastolic heart failure.

According to the analyses, Entresto shows considerably more promise than valsartan in reducing hospitalizations and fatalities from cardiovascular ailments, in certain subgroups. Greater advantage was observed in recently hospitalized HFpEF patients and female HFpEF patients.

Additionally, in a group analysis of PARADIGM-HF (HFrEF) and PARAGON-HF (HFpEF), treatment benefits were more prominent in patients with LVEF (left ventricular ejection fraction) less than 60%. Currently there is so approved treatment for HFpEF, which occurs disproportionately among women.

The new findings from the trial were revealed at the American Heart Association or AHA Scientific Session 2019. Publications of hospitalization analysis in the Journal of the American College of Cardiology and gender analysis in Circulation were also released simultaneously.

Entresto is presently an approved and vital treatment for HFrEF patients, generally involving less than or equal to 40% ejection fraction. This approval is based on its supremacy over enalapril, an ACE or angiotensin-converting enzyme. This superiority helps the drug reduce cardiovascular fatalities and hospitalizations due to heart failure, as revealed in the PARADIGM-HF trial.

Director of Noninvasive Cardiology at Brigham & Women’s Hospital, Harvard Medical School Professor and Executive Committee Co-Chair of PARAGON-HF, Scott Solomon, M.D., has apparently claimed that these new results demonstrate the benefits of Entresto in patients beyond HFrEF threshold. He further stated that these analyses would help gain a deeper understanding of HFpEF’s heterogeneous nature and unlock the potential advantage of Entresto for patients with unmet treatment needs.

PARAGON-HF Phase III complete results were presented at the 2019 ESC Congress. The study revealed a 13% relative decrease in the number of cardiovascular hospitalizations and deaths, narrowly missing statistical significance.
 

Source Credit: https://www.novartis.com/news/media-releases/novartis-paragon-hf-analyses-suggest-entresto-benefit-beyond-hfref



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

GE Healthcare Life Sciences & ASLS unite to advance 3D biofabrication
GE Healthcare Life Sciences & ASLS unite to advance 3D biofabrication
By Pankaj Singh

 

  • The alliance is aimed at personalizing regenerative tissue manufacturing processes
  • Vascularized printed cells are set to pave the way for more complex biolog...

Hummingbird Bio secures $19M to expand antibody therapeutics portfolio
Hummingbird Bio secures $19M to expand antibody therapeutics portfolio
By Pankaj Singh

Hummingbird Bioscience, an advanced biotherapeutics company, recently announced it has raised USD 19 million in a Series B funding round. Apparently, the financing round was co-led by GNTech Venture Capital and Mirae A...

Acadia announces positive results of Phase 3 trial to treat psychosis
Acadia announces positive results of Phase 3 trial to treat psychosis
By Pankaj Singh

Acadia Pharmaceuticals, a renowned US-based biopharmaceutical company dedicated to the development of treatments for central nervous system disorders, reportedly announced positive outcomes from its Phase 3 HARMONY stu...